Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529178 | 0.85 | POLB (0.55) | ALDH1A1MAPTSMN1; SMN2GAARAB9A | |
| SCHEMBL5527031 | 0.82 | MAPT (0.56) | ALDH1A1MAPTSMN1; SMN2GAARAB9A | |
| SCHEMBL5531303 | 0.81 | PKM (0.56) | ALDH1A1MAPTHPGDSMN1; SMN2GAA | |
| SCHEMBL5538233 | 0.78 | NPSR1 (0.57) | ALDH1A1MAPTSMN1; SMN2GAAMAPK1 | |
| SCHEMBL5530519 | 0.76 | POLB (0.58) | ALDH1A1MAPTSMN1; SMN2GAARAB9A | |
| SCHEMBL8114736 | 0.76 | ALDH1A1 (0.64) | ALDH1A1MAPTHPGDSMN1; SMN2RAB9A | |
| SCHEMBL27766750 | 0.75 | RXFP1 (0.65) | ALDH1A1MAPTHPGDSMN1; SMN2MAPK1 | |
| SCHEMBL8777820 | 0.75 | ALDH1A1 (0.62) | ALDH1A1MAPTHPGDSMN1; SMN2RAB9A | |
| SCHEMBL5525562 | 0.75 | RAB9A (0.62) | ALDH1A1MAPTSMN1; SMN2RAB9AMAPK1 | |
| SCHEMBL27761062 | 0.74 | POLB (0.55) | ALDH1A1MAPTSMN1; SMN2GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | ALDH1A1 2069/4885MAPT 680/4885HPGD 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.